Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
用于抗癌治疗的水杨酸小分子 Stat3 抑制剂
基本信息
- 批准号:9069481
- 负责人:
- 金额:$ 48.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-08-01 至 2018-05-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityBackBindingBiochemicalBiochemistryBiologicalBiological AssayBiological AvailabilityBiological ProcessBiologyBrainBreastBreast Cancer ModelCellsCharacteristicsChemicalsChemistryClinicClinicalColonDNA BindingDataDevelopmentDimerizationDrug resistanceElectrophoretic Mobility Shift AssayEventGenerationsGlioblastomaGoalsGrowthHumanIn VitroLeadLicensingLungLung NeoplasmsMDA MB 231MDA-MB-468Malignant NeoplasmsMammary NeoplasmsMolecularMusNude MiceOralOvarianPancreasPharmaceutical ChemistryPharmaceutical PreparationsPharmacologic SubstancePharmacologyPhenotypePhosphotyrosinePropertyProstateProteinsRoentgen RaysSKBR3STAT proteinSafetySalicylic AcidsSeriesSolidStat3 proteinStructural ChemistrySurface Plasmon ResonanceTestingToxic effectWorkXenograft ModelXenograft procedureanaloganti-cancer therapeuticantitumor effectbasecancer cellcancer therapydrug candidatedrug discoverydrug efficacyfeedingimprovedin vivoinhibitor/antagonistmalignant breast neoplasmmeetingsmelanomaneoplastic cellnext generationnovelnovel therapeuticspancreatic cancer cellspre-clinicalprogramsresearch clinical testingsmall moleculesubcutaneoustranscription factortumortumor xenograft
项目摘要
DESCRIPTION (provided by applicant): Aberrantly-active Stat3 is detected in primary, metastatic and drug resistant tumor phenotypes and is a master regulator of events that promote cancer development and progression. Substantive work from us and others has validated that Stat3-selective inhibitors would be therapeutically useful for a variety of human cancers. Initial proof-of-concept studies from us demonstrated strong antitumor effects of the lead Stat3 inhibitors, S3I-201 and S3I-201.1066 in mouse xenografts of human breast cancer. In the present study, BP-1-102 and other BP-series of agents derived from S3I-201.1066 were characterized for their biochemical, biological and antitumor activities and found to possess strong inhibitory activities against aberrant Stat3 activity, with binding affinity (KD) of 504 nM,
and IC50 values of 0.7-15 ?M. In particular, BP-1- 102 and the newly-derived agents, XW-1-053 and SH-04-54 inhibited aberrant Stat3 DNA-binding activity outside and inside cells and induced antitumor cell effects against malignant cells harboring aberrant Stat3 activity at sub-micromolar (0.7-5 ?M) activities. Initial in vivo testing showed BP-1-102 strongly inhibit growth of human breast tumors in mouse xenografts. These very promising new chemical entities are among the most potent Stat3 inhibitors identified to date. Our objective is to pursue rigorous structural analyses of the leading agents' binding to Stat3 to derive structural data that will support a hypothesis-driven intensive medicinal chemistry effort to generate agents of optimum parameters for clinical development. We hypothesize that optimized analogs would potently inhibit Stat3 activity and functions in tumor cells, possess suitable in vivo bioavailability and have high antitumor efficacy in human tumor xenografts. To achieve the Aims and the Milestones, iterative rounds of optimization through chemistry, structural analysis, biochemistry/biology, and pharmacology efforts will be performed. Data from studies of the properties of agents in Aims 1 and 2 will be fed back into chemistry to guide the optimization and the cycle repeated until suitable agents are identified, which will be tested in Aim 3 for in vivo antitumor efficacy studies using human breast cancer models in mice. Our plan thereafter is to pursue advanced, pre-clinical IND enabling studies through the NCI's RAID program or to license out the 1-2 drug candidates to a pharmaceutical company for further pre-clinical development and eventually clinical testing.
描述(由申请人提供):在原发性、转移性和耐药性肿瘤表型中检测到异常活性的 Stat3,并且它是促进癌症发生和进展的事件的主要调节因子。我们和其他人的实质性工作已经证实 Stat3 选择性抑制剂对于多种人类癌症具有治疗作用。我们的初步概念验证研究表明,主要的 Stat3 抑制剂 S3I-201 和 S3I-201.1066 在人类乳腺癌的小鼠异种移植物中具有强大的抗肿瘤作用。在本研究中,对 BP-1-102 和其他源自 S3I-201.1066 的 BP 系列药物的生化、生物和抗肿瘤活性进行了表征,发现对异常 Stat3 活性具有很强的抑制活性,结合亲和力 (KD) 为 504 nM,
IC50 值为 0.7-15 μM。特别是,BP-1-102和新衍生的药物XW-1-053和SH-04-54抑制细胞内外异常的Stat3 DNA结合活性,并诱导针对具有亚微摩尔(0.7-5μM)活性的异常Stat3活性的恶性细胞的抗肿瘤细胞作用。初步体内测试表明 BP-1-102 强烈抑制小鼠异种移植物中人类乳腺肿瘤的生长。这些非常有前途的新化学实体是迄今为止发现的最有效的 Stat3 抑制剂之一。我们的目标是对主要药物与 Stat3 的结合进行严格的结构分析,以获得结构数据,这些数据将支持假设驱动的密集药物化学工作,从而生成具有最佳参数的药物用于临床开发。我们假设优化的类似物将有效抑制肿瘤细胞中 Stat3 的活性和功能,具有适当的体内生物利用度,并在人类肿瘤异种移植物中具有较高的抗肿瘤功效。为了实现目标和里程碑,将通过化学、结构分析、生物化学/生物学和药理学工作进行迭代优化。目标 1 和 2 中药物特性研究的数据将反馈到化学中,以指导优化和重复循环,直到确定合适的药物,这将在目标 3 中使用人类乳腺癌小鼠模型进行体内抗肿瘤功效研究进行测试。此后我们的计划是通过 NCI 的 RAID 计划进行先进的临床前 IND 研究,或将 1-2 种候选药物授权给一家制药公司,以进行进一步的临床前开发和最终的临床测试。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Heliotropiumides A and B, new phenolamides with N-carbamoyl putrescine moiety from Heliotropium foertherianum collected in Hawaii and their biological activities.
Heliotropiumides A 和 B,是从夏威夷收集的 Heliotropium fertherianum 中含有 N-氨基甲酰基腐胺部分的新型酚酰胺及其生物活性。
- DOI:10.1016/j.bmcl.2017.09.021
- 发表时间:2017
- 期刊:
- 影响因子:2.7
- 作者:Cai,You-Sheng;Sarotti,ArielM;Gündisch,Daniela;Kondratyuk,TamaraP;Pezzuto,JohnM;Turkson,James;Cao,Shugeng
- 通讯作者:Cao,Shugeng
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James K Turkson其他文献
James K Turkson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James K Turkson', 18)}}的其他基金
11th Annual Meeting of International Cytokine & Interferon Society
第十一届国际细胞因子年会
- 批准号:
10753947 - 财政年份:2023
- 资助金额:
$ 48.06万 - 项目类别:
STAT3, G6PD and TrxR as underlying mechanisms for antitumor responses to hirsutinolides
STAT3、G6PD 和 TrxR 作为多毛内酯类抗肿瘤反应的潜在机制
- 批准号:
9443606 - 财政年份:2017
- 资助金额:
$ 48.06万 - 项目类别:
STAT3, G6PD and TrxR as underlying mechanisms for antitumor responses tohirsutinolides
STAT3、G6PD 和 TrxR 作为毛毛素内酯类抗肿瘤反应的潜在机制
- 批准号:
10098001 - 财政年份:2017
- 资助金额:
$ 48.06万 - 项目类别:
STAT3, G6PD and TrxR as underlying mechanisms for antitumor responses tohirsutinolides
STAT3、G6PD 和 TrxR 作为毛毛素内酯类抗肿瘤反应的潜在机制
- 批准号:
10005721 - 财政年份:2017
- 资助金额:
$ 48.06万 - 项目类别:
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
用于抗癌治疗的水杨酸小分子 Stat3 抑制剂
- 批准号:
8370490 - 财政年份:2012
- 资助金额:
$ 48.06万 - 项目类别:
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
用于抗癌治疗的水杨酸小分子 Stat3 抑制剂
- 批准号:
8770667 - 财政年份:2012
- 资助金额:
$ 48.06万 - 项目类别:
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
用于抗癌治疗的水杨酸小分子 Stat3 抑制剂
- 批准号:
8676474 - 财政年份:2012
- 资助金额:
$ 48.06万 - 项目类别:
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
用于抗癌治疗的水杨酸小分子 Stat3 抑制剂
- 批准号:
8519385 - 财政年份:2012
- 资助金额:
$ 48.06万 - 项目类别:
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
用于抗癌治疗的水杨酸小分子 Stat3 抑制剂
- 批准号:
8856165 - 财政年份:2012
- 资助金额:
$ 48.06万 - 项目类别:
Therapeutic Application of Novel Stat3 Inhibitors in Breast and Pancreatic Cancer
新型 Stat3 抑制剂在乳腺癌和胰腺癌中的治疗应用
- 批准号:
7526222 - 财政年份:2008
- 资助金额:
$ 48.06万 - 项目类别:
相似国自然基金
基于Teach-back药学科普模式的慢阻肺患者吸入用药依从性及疗效研究
- 批准号:2024KP61
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Quench-Back保护的超导螺线管磁体失超过程数值模拟研究
- 批准号:51307073
- 批准年份:2013
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
CAREER: From Dynamic Algorithms to Fast Optimization and Back
职业:从动态算法到快速优化并返回
- 批准号:
2338816 - 财政年份:2024
- 资助金额:
$ 48.06万 - 项目类别:
Continuing Grant
One-step reconstruction of plastic waste back to its constituent monomers (ONESTEP)
将塑料废物一步重建回其组成单体(ONESTEP)
- 批准号:
EP/Y003934/1 - 财政年份:2024
- 资助金额:
$ 48.06万 - 项目类别:
Research Grant
On the origin of very massive back holes
关于巨大背洞的起源
- 批准号:
DP240101786 - 财政年份:2024
- 资助金额:
$ 48.06万 - 项目类别:
Discovery Projects
Back to our roots: Re-activating Indigenous biocultural conservation
回到我们的根源:重新激活本土生物文化保护
- 批准号:
FT230100595 - 财政年份:2024
- 资助金额:
$ 48.06万 - 项目类别:
ARC Future Fellowships
Collaborative Research: NSFGEO-NERC: MEZCAL: Methods for Extending the horiZontal Coverage of the Amoc Latitudinally and back in time (MEZCAL)
合作研究:NSFGEO-NERC:MEZCAL:扩展 Amoc 纬度和时间回水平覆盖范围的方法 (MEZCAL)
- 批准号:
2409764 - 财政年份:2023
- 资助金额:
$ 48.06万 - 项目类别:
Standard Grant
Collaborative Research: FuSe: Indium selenides based back end of line neuromorphic accelerators
合作研究:FuSe:基于硒化铟的后端神经形态加速器
- 批准号:
2328741 - 财政年份:2023
- 资助金额:
$ 48.06万 - 项目类别:
Continuing Grant
Brain Mechanisms of Chronic Low-Back Pain: Specificity and Effects of Aging and Sex
慢性腰痛的脑机制:衰老和性别的特异性和影响
- 批准号:
10657958 - 财政年份:2023
- 资助金额:
$ 48.06万 - 项目类别:
The Role of VEGF in the Development of Low Back Pain Following IVD Injury
VEGF 在 IVD 损伤后腰痛发展中的作用
- 批准号:
10668079 - 财政年份:2023
- 资助金额:
$ 48.06万 - 项目类别:
Relationships Between Pain-Related Psychological Factors, Gait Quality, and Attention in Chronic Low Back Pain
慢性腰痛中疼痛相关心理因素、步态质量和注意力之间的关系
- 批准号:
10679189 - 财政年份:2023
- 资助金额:
$ 48.06万 - 项目类别:
Psilocybin and Affective Function in Chronic Lower Back Pain and Depression
裸盖菇素与慢性腰痛和抑郁症的情感功能
- 批准号:
10626449 - 财政年份:2023
- 资助金额:
$ 48.06万 - 项目类别: